TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02803164

Intervention type: DEVICE
Group type: OTHER
Intervention: Wound Vacuum-assisted dressing
Description: The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
Study: NCT02070107

Intervention type: OTHER
Group type: OTHER
Intervention: On Plan
Description: On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance.
Study: NCT04167345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-814
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-814
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-814
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-814
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-814 for oral administration.
Study: NCT02155933

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling for later hormone measurements

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling for later hormone measurements
Study: NCT04357106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma obtained by aphaeresis from recovered patients.
Study: NCT00859365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Description: Real acupuncture treatment in real acupuncture points

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: No intervention
Description: Patients lay down for a period of 35 minutes without any treatment o intervention
Study: NCT04227756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 20 mg per os, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline
Description: Mescaline 300 mg or 500 mg per os, single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol)
Study: NCT00699348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Description: Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
Study: NCT04523974

Intervention type: PROCEDURE
Intervention: Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT
Description: 1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period.
Study: NCT00618748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg/day, oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg/day, oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg/day, oral, daily
Study: NCT01004757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOGI diet
Description: diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat diet
Description: traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
Study: NCT01944085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Syrup

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Syrup
Study: NCT01144585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning and postconditioning
Description: RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
Study: NCT00445887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levonorgestrel
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT02070861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventricular pacing and passive leg raise
Description: Ventricular pacing and passive leg raise
Study: NCT01707030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Brief Alcohol Intervention
Description: Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
Study: NCT05220592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based recovery training program
Description: The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
Study: NCT01449708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA NoNarc
Description: * patients in both groups receive antiemetic prophylaxis~* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~* postop management in both groups is similar in both groups
Study: NCT03723681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib is provided as 20 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib is provided as 20 mg tablets for oral administration
Study: NCT05434832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Distraction method

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local cold-vibration
Description: Distraction method
Study: NCT02971202

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic clamp
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic clamp
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic clamp
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: 20% dextrose
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.

Intervention type: DRUG
Group type: OTHER
Intervention: 20% dextrose
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.

Intervention type: DRUG
Group type: OTHER
Intervention: 20% dextrose
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
Study: NCT02831465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Subjects
Description: Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
Study: NCT02977104

Intervention type: OTHER
Group type: OTHER
Intervention: Maestro ECG
Description: Telemetry is obtained through the Maestro handheld ECG device.

Intervention type: OTHER
Group type: OTHER
Intervention: Maestro ECG
Description: Telemetry is obtained through the Maestro handheld ECG device.
Study: NCT03581331

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: orthoptic balance
Description: Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point
Study: NCT02944916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IryPump R Set
Study: NCT02485080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study: NCT02770521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC.
Study: NCT01886521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar drain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular drain
Study: NCT04031079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable tech with feedback
Description: an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable tech without feedback
Description: an armwrist device measuring physical activity level, no reporting back to the user

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
Study: NCT03534479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyclonal IgG
Description: Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
Study: NCT03341260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50mg Tab.
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Study: NCT03029013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
Study: NCT03450928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips
Study: NCT01668654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retigabine/ezogabine
Description: retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
Study: NCT01084551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SPM 962
Description: once a daily transdermal administration for 13 weeks
Study: NCT03806127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT02137408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid 200 mg
Description: Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid 1000 mg
Description: Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
Study: NCT02024971

Intervention type: DRUG
Intervention: Pioglitazone/metformin hydrochloride
Description: Pioglitazone/metformin hydrochloride combination tablets
Study: NCT01467492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection
Study: NCT01785368

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of guidelines
Description: The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline observation
Description: During this period of the study, baseline data will be collected.
Study: NCT01891266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-tourniquet assisted TKA
Description: The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tourniquet assisted TKA
Description: The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
Study: NCT01069445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3® probiotic blend
Description: Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AISA-5203-L fruit extracted terpene
Description: Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Argan oil
Description: Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Diet
Description: a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
Study: NCT02981836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: diluent of lyophilized vaccine
Description: The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study: NCT02009878

Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: tolvaptan
Description: Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
Study: NCT02410694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03665363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCOPE
Description: SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-study
Description: Active control consisting of directed self-studies on internet.